Xenon Pharmaceuticals (XENE) Q3 2024 earnings summary

Executive summary

• Advancing late-stage clinical development of azetukalner, a Kv7 potassium channel opener, for epilepsy and MDD, with robust long-term efficacy and safety data in over 600 patient-years of exposure in epilepsy.

• Phase III epilepsy program (X-TOLE2, X-TOLE3, X-ACKT) progressing, with X-TOLE2 topline data expected in H2 2025 and NDA submission planned.

• Phase III MDD program to initiate before year-end 2024, with additional phase II MDD data expected in H1 2025.

• Early-stage pipeline includes multiple Kv7 candidates, Nav1.7 inhibitors for pain, and Nav1.1 potentiators for Dravet syndrome, with IND filings planned for 2025.

• Recent appointment of Dr. Matthew Ronsheim as Chief Operating Officer to oversee R&D and commercial launch preparations.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $803.3 million as of September 30, 2024, down from $930.9 million at year-end 2023.

• Q3 2024 net loss was $62.8 million, compared to $48.5 million in Q3 2023, reflecting higher R&D and personnel costs.

• Research and development expenses rose to $57.0 million in Q3 2024, driven by late-stage clinical trials and increased headcount.

• General and administrative expenses increased to $16.7 million in Q3 2024, mainly due to higher headcount and stock-based compensation.

• Interest income for the nine months was $32.5 million, up $13.6 million year-over-year, due to higher balances and yields on marketable securities.

Outlook and guidance

• Sufficient cash runway to fund operations into 2027, supporting completion of late-stage clinical programs and pipeline advancement.

• Topline data from X-TOLE2 Phase 3 epilepsy trial anticipated in H2 2025; Phase 3 MDD trial initiation expected before year-end 2024.

• Multiple IND filings for new ion channel modulators expected in 2025, with first-in-human trials to follow.